All In MedTech

Device Trial Radar · NCT07537556

Comprehensive Prospective Comparison Of Two Robotic Platforms In Anatomical Lung Resections: Clinical Outcomes And Cost-utility Analysis

Comprehensive Prospective Comparison Of Two Robotic Platforms In Anatomical Lung Resections: Clinical Outcomes And Cost-utility Analysis.

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Apr 1, 2023

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 17, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal is to compare clinical outcomes, hospital costs, and cost-utility in patients undergoing anatomical lung resections with DaVinci Xi vs Versius platforms The main questions it aims to answer are: * Do patients that undergo an anatomical lung resection with DaVinci Xi have the same clinical outcomes (complications, stay...) than those who were operated with Versius? * Are anatomical lung resections performed with DaVinci Xi more expensive than those performed with Versius? * Are anatomical lung resection performed with DaVinci Xi more cost-effective than those performed with Versius? Participants already undergoing robotic anatomical lung resection as part of their regular medical care will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.

Conditions

  • Pulmonary Nodule, Solitary
  • Lung Cancer (NSCLC)
  • Pulmonary Metastases

Interventions

  • da Vinci Xi Surgical SystemDevice

    Robotic platform used to perform anatomical lung resection (lobectomy or segmentectomy)

  • Versius Surgical SystemDevice

    Robotic platform used to perform anatomical lung resection (lobectomy or segmentectomy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cost/utility ratioTime frame: Data will be collected preoperatively (baseline), at 1, 3, 6, and 12 months after surgery.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.